Morphological and biomolecular characteristics of subcentimetric invasive breast carcinomas in Sicily: A multicentre retrospective study in relation to trastuzumab treatment

Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, et al: AJCC cancer staging handbook: TNM classification of malignant tumours. 6th edition. Wiley; New York: 2002, View Article : Google Scholar

Goldhirsch A, Gelber RD, Viale G, Colleoni M and Coates AS: Prediction of cancer outcome with microarrays. Lancet. 365:1685–1686. 2005. View Article : Google Scholar

Hanrahan EO, Valero V, Gonzalez-Angulo AM and Hortobagyi GN: Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature. J Clin Oncol. 13:2113–2122. 2006. View Article : Google Scholar : PubMed/NCBI

Spector NL and Blackwell KL: Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 34:5838–5847. 2009. View Article : Google Scholar : PubMed/NCBI

Curigliano G, Viale G, Bagnardi V, Fumagalli L, Locatelli M, Rotmensz N, Ghisini R, Colleoni M, Munzone E, Veronesi P, Zurrida S, Nolè F and Goldhirsch A: Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol. 34:5693–5699. 2009. View Article : Google Scholar : PubMed/NCBI

Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F, Peintinger F, Hanrahan EO, Sahin A, Guray M, Larsimont D, Feoli F, Stranzl H, Buchholz TA, Valero V, Theriault R, Piccart-Gebhart M, Ravdin PM, Berry DA and Hortobagyi GN: High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol. 34:5700–5706. 2009. View Article : Google Scholar : PubMed/NCBI

Burstein HJ and Winer EP: Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy. J Clin Oncol. 34:5671–5673. 2009. View Article : Google Scholar

Crivellari D and Molino A: Small tumor size and node-negative HER2-positive breast cancer: a step forward for a better treatment? J Clin Oncol. 16:e2572010. View Article : Google Scholar : PubMed/NCBI

Curigliano G, Viale G, Bagnardi V, Fumagalli L, Locatelli M, Rotmensz N, Ghisini R, Colleoni M, Munzone E, Veronesi P, Zurrida S, Nolè F and Goldhirsch A: Reply to D. Crivellari et al. J Clin Oncol. 16:e2582010. View Article : Google Scholar

Petrelli F and Barni S: Should adjuvant trastuzumab be offered in very early-stage (pT1a/bN0M0) HER2-neu-positive breast cancer? A current debate. Med Oncol. View Article : Google Scholar : 2010.PubMed/NCBI

Sciacca S, Sciacchitano S, Fidelbo M, Benedetto G, Madeddu A, Vasquez E, Cordio S, Caltavituro G, Castaing M, Cutello P, Pesce P, Ragusa R, Sciacchitano C and Torrisi A and Torrisi A: Breast neoplasms in the Province of Catania: data from the Integrated Neoplasms Registry, Catania-Messina-Siracusa, 2003–2005. Epidemiol Prev. 33:59–69. 2009.PubMed/NCBI

Rosen PP and Oberman H: Tumours of the mammary gland. Washington DC: Armed Forces Institute of Pathology; 1993

Elston CW and Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 41:151–152. 2002.

Joensuu H, Isola J, Lundin M, Salminen T, Holli K, Kataja V, Pylkkänen L, Turpeenniemi-Hujanen T, von Smitten K and Lundin J: Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res. 3:923–930. 2003.

Chia S, Norris B, Speers C, Cheang M, Gilks B, Gown AM, Huntsman D, Olivotto IA, Nielsen TO and Gelmon K: Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol. 35:5697–5704. 2008. View Article : Google Scholar : PubMed/NCBI

Giordano L, Giorgi D, Piccini P, Ventura L, Stefanini V, Senore C, Paci E and Segnan N: Time trends of process and impact indicators in Italian mammography screening programmes 1996–2004. Epidemiol Prev. 31:21–32. 2007.

Giorgi D, Giordano L, Ventura L, Frigerio A, Paci E and Zappa M: Mammography screening in Italy: 2005 survey and 2006 preliminary data. Epidemiol Prev. 32:7–22. 2008.PubMed/NCBI